Search the Newsreel

Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test

Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, causing its stock price to drop significantly. Despite a current "undervalued" narrative with a fair value of $434.72 against its $227.12 close, …

Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318

Stifel has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US) and maintained its target price of $318. This indicates the firm's continued confidence in the company's stock performance.

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for potential violations of federal securities laws. This follows Alnylam's announcement on July 30, 2026, where the company lowered its full-year 2026 TTR product sales guidance by approximately …

Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)?

Alnylam Pharmaceuticals reported strong Q2 2026 revenues of US$1.29 billion and net income of US$164.49 million, with H1 revenues reaching US$2.46 billion and net income at US$370.49 million. However, the company adjusted its full-year 2026 guidance, lowering net product revenue expectations while increasing collaboration …

Handelsbanken Fonder AB Sells 29,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Handelsbanken Fonder AB reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 21.4% in the second quarter, selling 29,207 shares and retaining 107,255 shares valued at $32.3 million. Despite this, institutional investors collectively own 92.97% of the company's stock, with several major funds increasing their …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop significantly. The investigation encourages investors who purchased Alnylam securities to connect with the …

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals (NASDAQ: ALNY) has shown significant outperformance over the past two decades, with an annualized return of 15.23%. An initial investment of $1000 in ALNY stock 20 years ago would now be valued at $17,192.61. This highlights the substantial impact of compounded returns …

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Exploring a 71% Potential Upside Amid Strong Revenue Growth

PensionDanmark Pensionsforsikringsaktieselskab Sells 12,119 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

PensionDanmark Pensionsforsikringsaktieselskab reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 35.1% in the second quarter, selling 12,119 shares and retaining 22,451 shares valued at $6.76 million. The stock opened at $219.20, significantly below its 52-week high, with institutional investors owning nearly 93% of the …

Alnylam Pharmaceuticals, Inc. (ALNY) latest press releases and corporate news

This article provides a compilation of recent press releases and corporate news related to Alnylam Pharmaceuticals (ALNY). It lists various announcements from the last several months, including financial results, biomarker collaboration reports, webcast details for earnings calls, and updates on neuroscience programs. The page …

Empowered Funds LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Empowered Funds LLC significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 72.2% in the first quarter, selling 14,021 shares and retaining 5,410 shares valued at $1.79 million. Despite this, analysts maintain a "Moderate Buy" consensus rating, although some major firms recently cut their …

Research Analysts Offer Predictions for ALNY Q3 Earnings

Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history

This article provides a comprehensive overview of Alnylam Pharmaceuticals, Inc. (ALNY), including its current stock price, recent performance metrics, and key financial data. It details the company's various therapeutic products, both commercialized and in different phases of clinical trials, focusing on its RNA interference-based …

Alnylam Pharmaceuticals (ALNY) On Lowered TTR Guidance And What It Means For Valuation

Alnylam Pharmaceuticals (ALNY) experienced a significant intraday share price drop following lowered 2026 TTR product sales guidance, despite strong quarterly revenues. The company's stock has been under pressure for much of 2026, yet analysts maintain a consensus price target of $434.72, suggesting it is …

Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options

Implied volatility for Alnylam Pharmaceuticals (ALNY) stock options is surging, particularly for the Sep 18, 2026 $170 Call, indicating that the market expects a significant price movement. Despite this, analysts currently rate Alnylam Pharmaceuticals as a Zacks Rank #3 (Hold), with recent downward revisions …

Alnylam Pharmaceuticals, Inc. (ALNY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. The firm is encouraging investors who purchased …

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of its stockholders. This investigation follows Alnylam's announcement of lowered TTR product sales guidance for full-year 2026, leading to a significant drop in its stock price. Investors …

ALNYLAM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $455 FROM $485

H.C. Wainwright has revised its target price for Alnylam Pharmaceuticals, Inc. (ALNY) shares, lowering it to $455 from the previous $485. This report, disseminated by Reuters, indicates an updated analyst perspective on the company's valuation. The content emphasizes that this analysis is an opinion …

Alnylam (ALNY) Turns Profitable as Revenue Mix Shifts: What Changes in Its Investment Story?

Alnylam Pharmaceuticals (ALNY) turned profitable in Q2 2026, reporting US$1,290.95 million in revenue and US$164.49 million in net income. The company also updated its full-year guidance, trimming net product revenue expectations while increasing collaboration and royalty revenue forecasts, indicating a shift in its sales …

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by Alnylam Pharmaceuticals, Inc. (ALNY). This probe follows Alnylam's announcement on July 30, 2026, of lowered full-year 2026 product sales guidance due to slower-than-expected growth in the second-line ATTR-CM market, which caused …

ALNYLAM PHARMACEUTICALS INC : RAYMOND JAMES CUTS TARGET PRICE TO $420 FROM $468

Raymond James has adjusted its target price for Alnylam Pharmaceuticals Inc., lowering it to $420 from the previous $468. This change indicates an updated outlook from the financial firm regarding the biotechnology company's valuation.

Enterprise value to revenue forward of Alnylam Pharmaceuticals, Inc – BX:DUL

This article provides the enterprise value to revenue forward for Alnylam Pharmaceuticals, Inc (BX:DUL). It appears to be a financial data point from TradingView, indicating a specific valuation metric for the company. The page primarily contains navigation and footer information typical of a financial …

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation

Alnylam Pharmaceuticals (NASDAQ:ALNY) presents an "affordable growth" opportunity, combining strong earnings and revenue expansion with a reasonable valuation relative to its biotech peers. The company demonstrates high growth rates, favorable forward estimates, and meets minimum thresholds for profitability and financial health, despite some reliance …

Alnylam (ALNY) Stock Stalls As TTR Sales Top $1b And Guidance Tightens

Alnylam Pharmaceuticals reported blockbuster second-quarter TTR drug revenues of $1.2 billion, with global transthyretin amyloidosis revenue exceeding $1 billion for the first time, yet its stock remained flat. The company turned profitable on a trailing twelve-month basis, posting significant non-GAAP operating income, but tightened …

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby

Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals, Inc. following a significant drop in share price. This investigation comes after Alnylam lowered its full-year 2026 TTR product sales guidance, citing normalization of growth in the ATTR-CM market. Shareholders who purchased …

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals reported strong second-quarter 2026 financial results, with global net product revenues of $1,172 million, a 74% increase from Q2 2025, primarily driven by their TTR franchise. Despite revising full-year 2026 TTR net product revenue guidance downwards slightly due to a normalization of …

ALNYLAM PHARMACEUTICALS INC : BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $346 FROM $410

BofA Global Research has lowered its price objective for Alnylam Pharmaceuticals Inc. (ALNYLAM PHARMACEUTICALS INC) from $410 to $346. This information was reported by Reuters on July 31, 2026. The article indicates that the content reflects only the author's opinion and is not investment …

ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut

Morgan Stanley Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Narrow-Moat Alnylam Navigates a Highly Competitive ATTR Market

Alnylam Pharmaceuticals, a pioneer in RNA interference therapeutics, faces a competitive market for its ATTR franchise. The company's strategy involves creating small interfering RNA (siRNA) to treat diseases at the genetic level, a potentially transformative technology. Recent reports indicate investor concern regarding the future …

Alnylam Lowers 2026 TTR Guidance As Amvuttra Forecast Comes Back To Earth

Alnylam Pharmaceuticals has lowered its 2026 TTR guidance, indicating a recalibration of its Amvuttra forecast. This update suggests a more conservative outlook for the drug's performance in the coming years. The change in guidance reflects evolving market expectations for Alnylam's key therapeutic.

Alnylam plunges as earnings deliver ‘one-two punch’

Alnylam Pharmaceuticals experienced a nearly 30% drop in market value after lowering its financial forecasts for its key drug franchise, Amvuttra and Onpattro, by $200 million. This guidance cut, unexpected by many analysts, comes after a previous setback in July from a study involving …

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Alnylam Pharmaceuticals lowered its fiscal year 2026 sales guidance for TTR products, citing normalizing second-line demand for Amvuttra. This news caused the stock to tank by over 29%. Despite the reduced outlook and the recent failure of a rival's ATTR-CM trial, Alnylam reaffirmed its …